

BET  
4-17-02  
#51IDSIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In regard to the application of: Nissim DARVISH, et al.

Serial No: 09/914,889

Group Art Unit: 3737

Filing Date: January 24, 2002

Examiner: To be assigned

For: BLOOD GLUCOSE LEVEL CONTROL

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents and Trademarks

Washington, DC 20231

Sir:

Applicants respectfully direct the attention of the Examiner to art cited with respect to U.S. Application No. 09/914,889.

The Examiner is respectfully requested to review and consider this art, in accordance with MPEP 2001.06, MPEP 1893.03(e) and MPEP 1893.03(g) and to indicate in the first office action that he has considered this art. Additionally, the Examiner is respectfully requested to cite those prior art publications mentioned in this application which the Examiner considers to be material or relevant to the present claims.

Further, in order to comply with discretionary regulations 37 CFR 1.97 and 1.98, attached is Form PTO-1449 listing the cited art. Also attached are copies<sup>1</sup> of the art. This art contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

In accordance with MPEP Section 609 it is requested that each document cited [including any mentioned in Applicants' specification which is not repeated on the attached (or prior) PTO-1449 form(s)] be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on the PTO-1449 form, so that it

<sup>1</sup> To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the national stage file. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such an equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited then none is known to the undersigned.

will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37CFR 1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,  
Nissim DARVISH, et al.

Paul Fenster

Paul FENSTER,  
Registration No. 33,877

March 25, 2002

William H. Dippert, Esq.  
Cowan, Liebowitz and Latman, P.C.  
1133 Avenue of the Americas  
New York, NY 10036-6799  
Tel: (212) 790-9200


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
015/02367

In Re Application Of: **Nissim DARVISH, et al.**


Serial No.	Filing Date	Examiner	Group Art Unit
09/914,889	January 24, 2002	Unknown	3737

Title: **BLOOD GLUCOSE LEVEL CONTROL**



Address to:

Assistant Commissioner for Patents  
Washington, D.C. 20231



**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

**OR**

the fee set forth in 37 CFR 1.17(p).


FIRST CLASS MAIL CERTIFICATE

Date of Deposit March 29, 2002

I hereby certify that the attached correspondence is being deposited with the U.S. Postal Service as with sufficient postage for First Class Mail in an envelope addressed to Box Issue Fee, Assistant Commissioner for Trademarks, Washington, D.C. 20231, on the date indicated above.

R. Lewis Gable

Name of Person Mailing



Signature